Apollo Endosurgery Inc (APEN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Apollo Endosurgery Inc (APEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10041
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Apollo Endosurgery Inc (Apollo Endo), formerly Lpath Inc, is a medical technology company that designs, develops and commercializes medical devices used for the treatment of obesity. The company’s product portfolio comprises endo-bariatric products such as Orbera Intragastric Balloon System and OverStitch endoscopic suturing system; and Lap-Band system for laparoscopic bariatric surgeries. These surgical and non-surgical interventional devices are also used in procedures that address or repair a variety of gastrointestinal defects. Apollo Endo’s products are used by bariatric surgeons, general surgeons and gastroenterologists. It has a manufacturing facility in the Coyol Free Trade Zone in Alajuela, Costa Rica. Apollo Endo is headquartered in Austin, Texas, the US.

Apollo Endosurgery Inc (APEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Apollo Endosurgery Inc, Medical Devices Deals, 2012 to YTD 2018 9
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To US$110 Million 11
Merger 13
Lpath and Apollo Endosurgery Merges 13
Equity Offering 14
Apollo Endosurgery Raises USD23.7 Million in Public Offering of Shares 14
Apollo Endosurgery to Raise up to USD16 Million in Public Offering of Shares 15
Apollo Endosurgery Raises USD36 Million in Public Offering of Shares 16
Lpath Raises USD12.5 Million in Private Placement of Shares 18
Lpath Files Registration Statement For Public Offering Of Class A Common Stock For Up To US$20 Million 20
Lpath Files Registration Statement For Public Offering Of Securities For Up To US$40 Million 21
Lpath Completes Public Offering Of Shares For US$12 Million 22
Lpath Announces Public Offering Of Class A Common Stock For US$9.3 Million 23
Asset Transactions 24
Pfizer Plans To Sell Certain Ohthalmology R&D Assets 24
Apollo Endosurgery Inc – Key Competitors 25
Apollo Endosurgery Inc – Key Employees 26
Apollo Endosurgery Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 08, 2018: Apollo Endosurgery reports second quarter 2018 results 28
May 03, 2018: Apollo Endosurgery Reports First Quarter 2018 Results 30
Mar 01, 2018: Apollo Endosurgery Reports Fourth Quarter and Full Year 2017 Results 31
Oct 26, 2017: Apollo Endosurgery Reports Third Quarter 2017 Results 33
Aug 01, 2017: Apollo Endosurgery Reports Second Quarter 2017 Results 35
Jul 12, 2017: Apollo Endosurgery Reports Preliminary Unaudited Financial Estimates for the Second Quarter of 2017 37
May 04, 2017: Apollo Endosurgery Reports First Quarter 2017 Results 38
Mar 08, 2017: Apollo Endosurgery Reports Fourth Quarter and Full Year 2016 Results 39
Corporate Communications 41
May 31, 2018: Apollo Endosurgery Appoints Dr. Julie Shimer to Board of Directors 41
Nov 16, 2017: David C. Pacitti Joins Apollo Endosurgery Board of Directors 42
Jan 17, 2017: Apollo Endosurgery Appoints Dr. Christopher J. Gostout as Chief Medical Officer 43
Government and Public Interest 44
Jun 25, 2018: Two diabetes medications don’t slow progression of type 2 diabetes in youth 44
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apollo Endosurgery Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Apollo Endosurgery Inc, Medical Devices Deals, 2012 to YTD 2018 9
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To US$110 Million 11
Lpath and Apollo Endosurgery Merges 13
Apollo Endosurgery Raises USD23.7 Million in Public Offering of Shares 14
Apollo Endosurgery to Raise up to USD16 Million in Public Offering of Shares 15
Apollo Endosurgery Raises USD36 Million in Public Offering of Shares 16
Lpath Raises USD12.5 Million in Private Placement of Shares 18
Lpath Files Registration Statement For Public Offering Of Class A Common Stock For Up To US$20 Million 20
Lpath Files Registration Statement For Public Offering Of Securities For Up To US$40 Million 21
Lpath Completes Public Offering Of Shares For US$12 Million 22
Lpath Announces Public Offering Of Class A Common Stock For US$9.3 Million 23
Pfizer Plans To Sell Certain Ohthalmology R&D Assets 24
Apollo Endosurgery Inc, Key Competitors 25
Apollo Endosurgery Inc, Key Employees 26
Apollo Endosurgery Inc, Other Locations 27
Apollo Endosurgery Inc, Subsidiaries 27

List of Figures
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Apollo Endosurgery Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Apollo Endosurgery Inc (APEN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Beactica AB-製薬・医療分野:企業M&A・提携分析
    Summary Beactica AB (Beactica) is a drug discovery company that focuses on the development of novel therapeutics. The company offers wide range of services such as fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis and antibody interaction …
  • Data Respons ASA (DAT):企業の財務・戦略的SWOT分析
    Summary Data Respons ASA (Data Respons) is an information technology company that offers software products and embedded solutions. The company's products include storage and memory, handheld tablets, embedded boards, panel PCs and displays, systems and platforms, and industrial communication product …
  • Sbarro, LLC:企業の戦略・SWOT・財務情報
    Sbarro, LLC - Strategy, SWOT and Corporate Finance Report Summary Sbarro, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Lung Biotechnology PBC:製薬・医療:M&Aディール及び事業提携情報
    Summary Lung Biotechnology PBC (LBI), formerly Lung Biotechnology Inc, is a subsidiary of United Therapeutics Corp, is a biotechnology company that develops and commercializes new therapies for the treatment of PAH and other fatal lung diseases. The company provides product such as Adcirca and Tyvas …
  • Publix Super Markets Inc (PUSH):企業の財務・戦略的SWOT分析
    Publix Super Markets Inc (PUSH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Gujarat State Electricity Corporation Ltd:企業の戦略的SWOT分析
    Gujarat State Electricity Corporation Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Camurus AB (CAMX):企業の財務・戦略的SWOT分析
    Summary Camurus AB (Camurus), a subsidiary of Sandberg Development AB, is a pharmaceutical company that carries out development and commercialization of treatments for the patients suffering from chronic diseases. The company’s technology includes smart and versatile drug delivery, injection depot, …
  • EKF Diagnostics Holdings Plc (EKF):医療機器:M&Aディール及び事業提携情報
    Summary EKF Diagnostics Holdings Plc (EKF Diagnostics) is a medical device company that designs, develops, manufactures, and commercializes point-of-care (POC) devices and tests and chemical reagents used for manufacturing in central laboratories. Its POC range includes hemoglobin analyzers, glucose …
  • Hyundai Motor Co (005380):企業の財務・戦略的SWOT分析
    Hyundai Motor Co (005380) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • AstraZeneca Plc (AZN):企業の財務・戦略的SWOT分析
    AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Chesapeake Energy Corp (CHK):石油・ガス:M&Aディール及び事業提携情報
    Summary Chesapeake Energy Corp (Chesapeake) is an upstream oil and gas company in the US. The company explores for, develops and produces oil and gas from its assets. It has liquid operations in Eagle Ford Shale; the Utica Shale; the Granite Wash, Cleveland, Tonkawa and Mississippian Lime plays in t …
  • Acura Pharmaceuticals Inc (ACUR):医療機器:M&Aディール及び事業提携情報
    Summary Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tamp …
  • Avalign Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Avalign Technologies Inc (Avalign), a subsidiary of Arlington Capital Partners, is a medical device company that supplies surgical implants, instruments, and delivery systems. The company offers precision machined instruments, cutting instruments, delivery systems, cases and trays, german sp …
  • HD Supply, Inc. (HDS):企業の財務・戦略的SWOT分析
    HD Supply, Inc. (HDS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Genedata AG-医療機器分野:企業M&A・提携分析
    Summary Genedata AG (Genedata) is a healthcare technology company that transforms data into software solutions. The company delivers enterprise solutions for data analytics that streamline research and development workflows and improve research productivity. Its products include genedata biologics, …
  • Jagatjit Industries Limited:企業の戦略・SWOT・財務情報
    Jagatjit Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Jagatjit Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Torishima Pump Mfg Co Ltd (6363):企業の財務・戦略的SWOT分析
    Torishima Pump Mfg Co Ltd (6363) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Futuren (FTRN):企業の財務・戦略的SWOT分析
    Futuren (FTRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • AGL Energy Ltd (AGL)-エネルギー分野:企業M&A・提携分析
    Summary AGL Energy Limited (AGL) is an integrated energy company that owns, operates and develops energy assets and provides natural gas, electricity, solar photovoltaic solutions and related products and services. The company’s power generation portfolio includes coal, gas, hydro, wind, solar, land …
  • Smurfit Kappa Group plc:企業の戦略・SWOT・財務情報
    Smurfit Kappa Group plc - Strategy, SWOT and Corporate Finance Report Summary Smurfit Kappa Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆